Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Sep 14, 2013; 19(34): 5706-5712
Published online Sep 14, 2013. doi: 10.3748/wjg.v19.i34.5706
Published online Sep 14, 2013. doi: 10.3748/wjg.v19.i34.5706
Efficacy of treatment with rebamipide for endoscopic submucosal dissection-induced ulcers
Masaki Takayama, Shigenaga Matsui, Masanori Kawasaki, Yutaka Asakuma, Toshiharu Sakurai, Hiroshi Kashida, Masatoshi Kudo, Department of Gastroenterology and Hepatology, Kinki University, Osaka 589-8511, Japan
Author contributions: Takayama M and Matsui S contributed equally to this work; Takayama M, Matsui S, Kawasaki M, Asakuma Y, Sakurai T, Kashida H and Kudo M designed the research; Takayama M and Matsui S performed the research; Takayama M and Matsui S analyzed the data; Takayama M wrote the paper.
Correspondence to: Masaki Takayama, MD, Department of Gastroenterology and Hepatology, Kinki University, 377-2 Ohno-Higashi, Osaka-Sayama, Osaka 589-8511, Japan. masaki0742@yahoo.co.jp
Telephone: +81-72-3660221 Fax: +81-72-3672880
Received: June 9, 2013
Revised: July 25, 2013
Accepted: August 8, 2013
Published online: September 14, 2013
Revised: July 25, 2013
Accepted: August 8, 2013
Published online: September 14, 2013
Core Tip
Core tip: In this prospective randomized, parallel-controlled study, we demonstrated that rebamipide monotherapy was as effective as proton-pump inhibitor (PPI) in the healing of endoscopic submucosal dissection-induced ulcers, regardless of the location of the resected cancer, the degree of atrophic gastritis, or the presence of Helicobacter pylori infection. In addition, rebamipide treatment is more cost-effective and results in a better quality of ulcer healing compared with the PPI lansoprazole.